An interventional study of BLAZE (Brain health Lifestyle Action with personaliZed Engagement) in MCI and Dementia, sponsored by Alexandra Hospital. Not yet recruiting at 1 site in Singapore. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Alexandra Hospital · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Dementia with a site in Singapore — 7 open to participants now, 9 under way, none of them phase 3. Dementia · Singapore.
Among the 25 studies in Dementia with a site in Singapore, this one is the 8th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2026, is one of 14 with no phase, and was the 24th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →7 of the 25 studies in Dementia with a site in Singapore are open now. Recruiting first, the newest first:
National University of Singapore · Sites in Singapore
Ages 45–80 · Healthy volunteers
National Cancer Centre, Singapore · Sites in Singapore
Ages 50–99
Eli Lilly and Company · Sites in Singapore, United States, Australia and 1 more country
Ages 50–85
Duke-NUS Graduate Medical School · Sites in Singapore
Ages 21–80 · Healthy volunteers
Vincent Tay Khwee Soon · Sites in Singapore
Ages 50–80
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 3
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 225 across the 22 interventional studies, 400 across the 3 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
Alexandra Hospital is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Alexandra Hospital has 1 study filed under Dementia — fewer than ten, so there is no comparison to draw.
3 of the studies in Dementia with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT07598370Eli Lilly and CompanyA Study of LY3439539 in Participants With Alzheimer's Disease | 2027-08 |
| NCT07234357National Cancer Centre, SingaporeSensory Enrichment Using Aromatherapy for Neurobehavioral and Psychological Symptoms in Early Dementia | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Dementia with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate whether an AI-powered digital brain health coaching intervention can improve modifiable brain health risk factors in community-dwelling adults aged 40 and above in Singapore.
The main question it aims to answer is: does the use of BLAZE, an AI-powered digital brain health coaching intervention, lead to a greater improvement in Brain Care Score (BCS) compared to usual care at 6 months?
Researchers will compare participants receiving BLAZE to those receiving usual care (waitlist control) to see if BLAZE leads to greater improvements in brain health risk factors, behavioural outcomes, quality of life, and cost-effectiveness.
Participants will:
Dementia represents a growing public health challenge in Singapore and across the Asia-Pacific region, with prevalence projected to rise substantially as the population ages. Up to 40% of dementia risk is attributable to modifiable lifestyle factors, highlighting significant potential for prevention through targeted behavioural interventions. Despite this, translating evidence-based lifestyle recommendations into sustained behavioural change in community settings remains a significant challenge, particularly given the limited time available for personalised guidance in primary care.
The THINK-SHARP trial evaluates BLAZE (Brain health Lifestyle Action with personaliZed Engagement), a theory-driven AI-powered digital coaching intervention designed to support brain health behaviours in community-dwelling adults. BLAZE is grounded in the Capability-Opportunity-Motivation-Behaviour (COM-B) framework, a well-established behavioural science model, and is delivered via a WhatsApp-based platform integrated with a large language model (LLM). The intervention operates through four integrated modules - Assessment, Education, Nudge, and Coaching - to deliver personalised recommendations, behavioural prompts, and goal-setting support tailored to each participant's individual brain health profile.
Personalisation is driven by the Brain Care Score (BCS), a validated composite measure of modifiable physical, lifestyle, and social-emotional risk factors for brain health. BLAZE uses each participant's BCS profile to identify priority areas for behavioural change and generates adaptive, data-driven recommendations accordingly. All content is informed by a curated knowledge base developed in collaboration with neurologists and geriatricians to ensure clinical relevance and safety.
The trial employs a two-arm, waitlist-controlled randomised controlled trial (RCT) design, with 350 participants randomised 1:1 to either the immediate intervention arm or the waitlist control arm. The immediate intervention arm receives BLAZE for 12 months, while the waitlist control arm receives usual care for the first 6 months before crossing over to receive BLAZE for a further 6 months. The primary outcome is the between-group difference in BCS at 6 months. Secondary outcomes assess changes across six domains: physical function, lifestyle behaviours, self-management and health engagement, cognitive function, quality of life, and social health.
Beyond clinical effectiveness, the trial incorporates a concurrent process evaluation to assess implementation outcomes including adherence, feasibility, usability, and perceived value of the intervention. A model-based health economic evaluation will also be conducted to estimate the long-term cost-effectiveness of BLAZE from the Singapore public healthcare payer perspective. Together, these components provide a comprehensive assessment of BLAZE's potential as a scalable, behaviourally grounded approach to community brain health promotion.
This trial also contributes novel evidence on the applicability of the Brain Care Score within a Southeast Asian community-dwelling population, extending its validation beyond previously studied settings and supporting its relevance for regional brain health promotion efforts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the waitlist control arm will receive usual care for the first 6 months of the study, consisting of standard educational materials on brain health. Following the 6-month assessment, waitlist control participants will receive full access to BLAZE for a further 6 months (months 6-12), identical to the intervention described in the immediate intervention arm.
Behavioral: BLAZE (Brain health Lifestyle Action with personaliZed Engagement)
Participants assigned to the immediate intervention arm will receive access to BLAZE (Brain health Lifestyle Action with personaliZed Engagement) for 12 months.
Behavioral: BLAZE (Brain health Lifestyle Action with personaliZed Engagement)
BLAZE is an AI-powered digital brain health coaching intervention delivered via a WhatsApp-based platform integrated with a large language model (LLM). Grounded in the COM-B behavioural framework, BLAZE operates through four integrated modules - Assessment, Education, Nudge, and Coaching - to deliver personalised recommendations, behavioural nudges, educational content, and goal-setting support. Personalisation is driven by each participant's Brain Care Score (BCS) profile, with intervention intensity stratified according to domain-specific scores. All content is informed by a curated knowledge base developed in collaboration with neurologists and geriatricians
Brain Care Score
To evaluate whether the AI-powered Brain Health Coach, BLAZE, improves BCS in community-dwelling adults versus usual care. Scores range from 0 to 45, with higher scores indicating better lifestyle habits, physical health, and social connection.
Time frame: 12 months
NHG Healthy Eating Score
A self-reported questionnaire assessing dietary habits aligned with brain health recommendations. Scores range from 0 to 100, with higher scores indicating healthier dietary behaviours. Improvement in score reflects adoption of healthier eating patterns across domains targeted by the intervention.
Time frame: 12 months
EuroQol-5 (EQ-5D)
A standardised measure of health-related quality of life assessing five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a scale of 1 (no problems) to 5 (extreme problems/unable to perform), generating a health utility index score where higher values indicate better health-related quality of life. Participants also rate their overall health on a Visual Analogue Scale (VAS) from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: 12 months
Lawton Instrumental Activities of Daily Living (IADL)
A self-reported measure assessing the ability to perform complex daily tasks such as managing finances, using transportation, preparing meals, and using the telephone. Scores range from 0 to 8, with higher scores indicating greater functional independence. This measure monitors maintenance of functional independence in community-dwelling adults over the course of the study.
Time frame: 12 months
Katz Index of Independence in Activities of Daily Living (ADL)
A measure assessing independence in six basic daily activities: bathing, dressing, toileting, transferring, continence, and feeding. Each activity is scored as independent (1) or dependent (0), yielding a total score of 0 to 6, where higher scores indicate greater independence. This measure monitors for any unexpected decline in basic functional independence during the study period.
Time frame: 12 months
UCLA Loneliness Scale (UCLA-3)
A 3-item self-reported measure assessing subjective feelings of loneliness and social isolation. Each item is rated on a scale of 1 (hardly ever) to 3 (often), with total scores ranging from 3 to 9. Higher scores indicate greater loneliness. A reduction in score reflects improved social connectedness targeted through the intervention's social engagement recommendations.
Time frame: 12 months
Lubben Social Network Scale (LSNS-6)
A 6-item self-reported measure assessing the size and frequency of a participant's social network, including family and friend contacts. Scores range from 0 to 30, with higher scores indicating stronger social networks. A score below 12 is considered indicative of social isolation risk. Improvement in score reflects strengthened social connections targeted through the intervention's social health domain recommendations.
Time frame: 12 months
Chair Stand Test
An objective performance-based measure of lower body strength and physical function. Participants are timed completing five sit-to-stand repetitions from a chair without using their arms. Faster completion times indicate better lower body strength and physical function. Improvement in performance reflects increased physical activity and strength targeted through the intervention's physical health recommendations.
Time frame: 12 months
Grip Strength
An objective measure of overall muscular strength assessed using a handheld dynamometer. Results are recorded in kilograms, with higher values indicating greater muscular strength. Improvement in grip strength reflects sustained engagement in physical activity behaviours targeted through the intervention.
Time frame: 12 months
Adapted Dementia Knowledge and Attitudes (14-item)
A 14-item adapted questionnaire assessing knowledge of dementia risk factors, symptoms, and prevention strategies, as well as attitudes towards dementia. Six items were adapted from the validated Dementia Knowledge and Attitudes Scale (DKAS) and ten items from a comparative analysis of dementia health literacy in Singapore. Higher scores indicate greater dementia knowledge and more positive attitudes towards dementia.
Time frame: 12 months
Partners in Health Scale (PIH)
A 12-item self-reported measure assessing self-management capacity across four domains: knowledge of condition, adherence to treatment, recognition and management of symptoms, and coping. Each item is rated on a scale of 0 to 8, with total scores ranging from 0 to 96. Higher scores indicate greater self-management capacity. Improvement in score reflects the intervention's coaching module supporting independent brain health management.
Time frame: 12 months
Rapid Assessment of Physical Activity (RAPA)
A self-reported questionnaire assessing aerobic physical activity levels and strength and flexibility behaviours. The aerobic component is scored from 1 to 7, where scores of 1-4 indicate sub-optimal activity levels and scores of 5-7 indicate recommended levels of moderate to vigorous physical activity. The strength and flexibility component is scored from 0 to 2. Higher scores across both components indicate more active lifestyle behaviours. Improvement reflects the intervention's physical activity nudges and goal-setting support.
Time frame: 12 months
Montreal Cognitive Assessment (MoCA)
A brief 30-item cognitive screening tool assessing multiple cognitive domains including memory, attention, language, visuospatial ability, and orientation. Scores range from 0 to 30, with higher scores indicating better cognitive function. A score of 26 or above is considered within the normal range. This measure provides a baseline cognitive profile and enables monitoring of any meaningful change in global cognitive function during the study period.
Time frame: 12 months
Plan to share: Undecided — A decision on whether and how individual participant data will be shared with external researchers has not yet been made. Plans for data sharing will be determined following completion of the trial and will be guided by applicable institutional policies, ethical considerations, and data governance requirements in Singapore.
Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 36 months is above that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alexandra Hospital